ASLN — Aslan Pharmaceuticals Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual balance sheet for Aslan Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	—	—	—	—	—
Source:	Annual Audited Accounts	20-F	20-F	20-F	20-F
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	28.9	22.2	14.5	90.2	56.9
Net Total Accounts Receivable
Net Total Receivables	0	0	0.529	0	—
Prepaid Expenses
Total Other Current Assets
Total Current Assets	29.1	22.3	15.5	93.8	60.9
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	0.288	0.766	0.476	0.233	0.293
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	52.9	23.3	16.1	94.5	61.2
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	8	5.38	10.7	6.36	23.2
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Minority Interest
Total Other Liabilities
Total Liabilities	22.3	25	26.5	37.2	52.8
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	30.6	-1.68	-10.5	57.3	8.37
Total Liabilities & Shareholders' Equity	52.9	23.3	16.1	94.5	61.2
Total Common Shares Outstanding